Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 2
1965 1
1968 1
1970 1
1971 2
1972 6
1973 18
1974 15
1975 30
1976 35
1977 29
1978 16
1979 18
1980 20
1981 24
1982 14
1983 22
1984 15
1985 11
1986 15
1987 17
1988 13
1989 9
1990 19
1991 22
1992 5
1993 13
1994 6
1995 12
1996 6
1997 6
1998 12
1999 7
2000 18
2001 8
2002 14
2003 32
2004 40
2005 44
2006 50
2007 71
2008 52
2009 64
2010 91
2011 112
2012 144
2013 135
2014 144
2015 185
2016 225
2017 282
2018 397
2019 585
2020 871
2021 836
Text availability
Article attribute
Article type
Publication date

Search Results

4,340 results
Results by year
Filters applied: . Clear all
Page 1
Cannabidiol Adverse Effects and Toxicity.
Huestis MA, Solimini R, Pichini S, Pacifici R, Carlier J, Busardò FP. Huestis MA, et al. Curr Neuropharmacol. 2019;17(10):974-989. doi: 10.2174/1570159X17666190603171901. Curr Neuropharmacol. 2019. PMID: 31161980 Free PMC article. Review.
BACKGROUND: Currently, there is a great interest in the potential medical use of cannabidiol (CBD), a non-intoxicating cannabinoid. Productive pharmacological research on CBD occurred in the 1970s and intensified recently with many discoveries about the endocannabinoid sys …
BACKGROUND: Currently, there is a great interest in the potential medical use of cannabidiol (CBD), a non-intoxicating cannabinoid. P …
Epilepsy and cannabidiol: a guide to treatment.
Arzimanoglou A, Brandl U, Cross JH, Gil-Nagel A, Lagae L, Landmark CJ, Specchio N, Nabbout R, Thiele EA, Gubbay O, The Cannabinoids International Experts Panel; Collaborators. Arzimanoglou A, et al. Epileptic Disord. 2020 Feb 1;22(1):1-14. doi: 10.1684/epd.2020.1141. Epileptic Disord. 2020. PMID: 32096470 Free article. Review.
The growing interest in cannabidiol (CBD), specifically a pure form of CBD, as a treatment for epilepsy, among other conditions, is reflected in recent changes in legislation in some countries. ...
The growing interest in cannabidiol (CBD), specifically a pure form of CBD, as a treatment for epilepsy, among other conditions, is r …
The potential of cannabidiol in the COVID-19 pandemic.
Esposito G, Pesce M, Seguella L, Sanseverino W, Lu J, Corpetti C, Sarnelli G. Esposito G, et al. Br J Pharmacol. 2020 Nov;177(21):4967-4970. doi: 10.1111/bph.15157. Epub 2020 Jul 16. Br J Pharmacol. 2020. PMID: 32519753 Free PMC article.
Identifying drugs effective in the new coronavirus disease 2019 (COVID-19) is crucial, pending a vaccine against SARS-CoV2. We suggest the hypothesis that cannabidiol (CBD), a non-psychotropic phytocannabinoid, has the potential to limit the severity and progression of the …
Identifying drugs effective in the new coronavirus disease 2019 (COVID-19) is crucial, pending a vaccine against SARS-CoV2. We suggest the h …
Cannabidiol as a Potential Treatment for Anxiety Disorders.
Blessing EM, Steenkamp MM, Manzanares J, Marmar CR. Blessing EM, et al. Neurotherapeutics. 2015 Oct;12(4):825-36. doi: 10.1007/s13311-015-0387-1. Neurotherapeutics. 2015. PMID: 26341731 Free PMC article. Review.
Cannabidiol (CBD), a Cannabis sativa constituent, is a pharmacologically broad-spectrum drug that in recent years has drawn increasing interest as a treatment for a range of neuropsychiatric disorders. ...
Cannabidiol (CBD), a Cannabis sativa constituent, is a pharmacologically broad-spectrum drug that in recent years has drawn increasin
The pharmacokinetics and the pharmacodynamics of cannabinoids.
Lucas CJ, Galettis P, Schneider J. Lucas CJ, et al. Br J Clin Pharmacol. 2018 Nov;84(11):2477-2482. doi: 10.1111/bcp.13710. Epub 2018 Aug 7. Br J Clin Pharmacol. 2018. PMID: 30001569 Free PMC article. Review.
Cannabis medicines contain a wide variety of chemical compounds, including the cannabinoids delta-9-tetrahydrocannabinol (THC), which is psychoactive, and the nonpsychoactive cannabidiol (CBD). Cannabis use is associated with both pathological and behavioural toxicity and, …
Cannabis medicines contain a wide variety of chemical compounds, including the cannabinoids delta-9-tetrahydrocannabinol (THC), which is psy …
Pharmacology of Medical Cannabis.
Amin MR, Ali DW. Amin MR, et al. Adv Exp Med Biol. 2019;1162:151-165. doi: 10.1007/978-3-030-21737-2_8. Adv Exp Med Biol. 2019. PMID: 31332738 Review.
The predominant psychotropic component is delta(9)-tetrahydrocannabinol (delta(9)-THC), while the major non-psychoactive ingredient is cannabidiol (CBD). These compounds have been shown to be partial agonists or antagonists at the prototypical cannabinoid receptors, CB1 an …
The predominant psychotropic component is delta(9)-tetrahydrocannabinol (delta(9)-THC), while the major non-psychoactive ingredient is ca
Cannabidiol in Anxiety and Sleep: A Large Case Series.
Shannon S, Lewis N, Lee H, Hughes S. Shannon S, et al. Perm J. 2019;23:18-041. doi: 10.7812/TPP/18-041. Perm J. 2019. PMID: 30624194 Free PMC article.
CONTEXT: Cannabidiol (CBD) is one of many cannabinoid compounds found in cannabis. ...In this chart review, CBD was well tolerated in all but 3 patients. CONCLUSION: Cannabidiol may hold benefit for anxiety-related disorders. Controlled clinical studies are needed.. …
CONTEXT: Cannabidiol (CBD) is one of many cannabinoid compounds found in cannabis. ...In this chart review, CBD was well tolerated in …
Practical considerations in medical cannabis administration and dosing.
MacCallum CA, Russo EB. MacCallum CA, et al. Eur J Intern Med. 2018 Mar;49:12-19. doi: 10.1016/j.ejim.2018.01.004. Epub 2018 Jan 4. Eur J Intern Med. 2018. PMID: 29307505 Review.
In this article, the authors endeavour to present concise data on cannabis pharmacology related to tetrahydrocannabinol (THC), cannabidiol (CBD) et al., methods of administration (smoking, vaporisation, oral), and dosing recommendations. ...
In this article, the authors endeavour to present concise data on cannabis pharmacology related to tetrahydrocannabinol (THC), cannabidio
Medical Cannabis.
Ebbert JO, Scharf EL, Hurt RT. Ebbert JO, et al. Mayo Clin Proc. 2018 Dec;93(12):1842-1847. doi: 10.1016/j.mayocp.2018.09.005. Mayo Clin Proc. 2018. PMID: 30522595 Review.
Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome.
Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, Scheffer IE, Thiele EA, Wright S; Cannabidiol in Dravet Syndrome Study Group. Devinsky O, et al. N Engl J Med. 2017 May 25;376(21):2011-2020. doi: 10.1056/NEJMoa1611618. N Engl J Med. 2017. PMID: 28538134 Free article. Clinical Trial.
The percentage of patients who became seizure-free was 5% with cannabidiol and 0% with placebo (P=0.08). Adverse events that occurred more frequently in the cannabidiol group than in the placebo group included diarrhea, vomiting, fatigue, pyrexia, somnolence, and ab …
The percentage of patients who became seizure-free was 5% with cannabidiol and 0% with placebo (P=0.08). Adverse events that occurred …
4,340 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page